CAVE CREEK, AZ--(Marketwired - Dec 15, 2015) - Endexx Corporation (
The study, supervised by Dr. Daniel Kiddy, DPM, is comprised of ten volunteer patients taking CBD-rich hemp oil sublingually for up to forty-five days. Two million patients are treated for Plantar Fasciitis in the US every year according to the American Academy of Orthopedic Surgeons. The condition is caused by the inflammation of the plantar fascia. Cannabidiol has been shown in multiple clinical studies to have powerful anti-inflammatory properties.
Dr. Kiddy, a foot and ankle specialist who treats plantar fasciitis patients on a daily basis, stated: "Many cases of plantar fasciitis occur due to nerve inflammation of the medial calcaneal branch coming off the posterior tibial nerve or from inflammation to the first branch off the lateral plantar nerve known as Baxter's nerve. The goal of the study is to record changes in pain levels for patients diagnosed with plantar fasciitis through the administration of CBD-rich oil provided by CBD Unlimited."
The diabetic neuropathy study started a year ago in Missouri has been concluded. Almost all of the 13 patients who participated in the trial experienced improvement. Improvement was described as being able to sleep, not wake up with pain, feeling more rested and increased energy. One of the patients had chronic migraine headaches, for which she was taking eighteen Imitrex per month in addition to Gabapentin and Zonisamize. The patient is now down to two Imitrex per month and is off her other two medications completely. Patients are now using CBD-rich hemp oil from CBD Unlimited instead of prescription medications, per their doctor's advice, with decreased pain and a better quality of life.
Todd Davis, CEO of Endexx, stated, "Through testimony of our clients and feedback from patients voluntarily participating in these studies, we are finding that secondary pain and inflammation related symptoms are improving through the use of our Phyto-Cannabinoid enriched blends. Testimonies come in weekly about the benefits provided by our products. We will continue to support baseline case studies that build a more complete understanding of the benefits derived from organic hemp extracts."
Endexx provides innovative medical marijuana management and technology solutions. Endexx, with its collaborative partners and consultants, develops and distributes two consumable product lines derived from industrial hemp, which is organic and naturally rich in phytocannabinoids. The company has two technology products and services that launched in 2014 -- the M3hub and the Autospense™. Both products provide essential solutions to promote regulatory compliance and full accountability through "seed to sale" inventory management and tracking. Based on principles developed by the pharmacological industry, the m3hub platform is the first standardized software solution for tracking pharmaceutical grade marijuana that maintains compliance with federal, state and local regulations. It is intended to provide a smooth transition to an eventual federal mandates. The Autospense™ is a high-tech marijuana inventory control and dispensing device that provides up-to-the-minute accounting details and ensures both product and patient security. By automating the dispensing process, Autospense™ increases productivity and reduces costs for marijuana retailer, while enhancing their service quality by reducing transaction time for customers. Websites include: www.cbdunlimited.com, www.cbdhealthsolutions.com, www.endexx.com, www.m3hub.com.
Safe Harbor Notice
This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the Company's business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company's periodic filings with the Security and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements.
For further investor and media information, contact:
Chairman & CEO